Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

IDT Winter Term Cancer Chemotherapy Subclasses > Antineoplastics > Flashcards

Antineoplastics Flashcards

(80 cards)

Start Studying
1
Q 
Alemtuzumab
MOA
Indication
SE's
DI
Comments
A

MOA - Anti CD52 MAB
Indication - CLL
SE’s - Immunosuppression, neutropenia, infusion related reactions
DI - Vaccines and immunosuppressants
Comments - interactions are not enzyme mediated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q 
Arsenic Trioxide
MOA
Indication
SE's
DI
Comments
A 
MOA - Differentiating agent
Indication - APL
SE's - Differentiation syndrome, neuropathies
DI - QT prolonging medications
Comments - NA
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q 
Azacitidine
MOA
Indication
SE's
DI
Comments
A 
MOA - Hypomethylating agent
Indication - AML, MDS
SE's - Myelosuppression, nausea
DI - Immune suppressants, echinacea
Comments - Delayed onset of effect (2-4 cycles)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q 
Belinostat
MOA
Indication
SE's
DI
Comments
A 
MOA - Histone deacetylase inhibitor
Indication - Peripheral T-cell lymphoma
SE's - Myelosuppression, nausea, fatigue
DI -UGT1A1 and PGP inhibitors or inducers
Comments - NA
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q 
Bendamustine
MOA
Indication
SE's
DI
Comments
A 
MOA - Alkylating agent
Indication - CLL, NHL
SE's - Myelosuppression, nausea, emesis
DI - CYP 1A2 inhibitors
Comments - N/A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q 
Bleomycin
MOA
Indication
SE's
DI
Comments
A 
MOA - inhibits DNA and RNA synthesis
Indication - HD, NHL
SE's - Pulmonary toxicity, hyper pigmentation, Raynauds
DI - Brentuximab vaccines
Comments - Lifetime max dose 400 units
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q 
Blinatumomab
MOA
Indication
SE's
DI
Comments
A

MOA - anti CD 19 MAB that links to cytotoxic T-cells
Indication - ALL
SE’s - Cytokine release syndrome, tumor lysis, leukoencephalopathy
DI - vaccines
Comments - murine antibody

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q 
Bortezomib
MOA
Indication
SE's
DI
Comments
A

MOA - Proteasome inhibitor
Indication - Myeloma, NHL
SE’s - Neuropathy, diarrhea, thrombocytopenia
DI - CYP 3A4 inducers, green tea, CYP 2C19 substrates
Comments - SQ administration decreases neuropathy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q 
Brentuximab vedotin
MOA
Indication
SE's
DI
Comments
A

MOA - Anti-CD 30 MAB linked to microtubule inhibitor
Indication - HD
SE’s - Rach, neuropathy, myelosuppression
DI - Bleomycin, CYP 3A4 inhibitors or inducers
Comments - Dosing maxed at 100kg (dosed per kg)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q 
Busulfan
MOA
Indication
SE's
DI
Comments
A

MOA - Alkylating agent
Indication - CML, used for BMT
SE’s - Myelosuppression, hyperpigementation, n/v, lowers seizure threshold, veto-occlusive disease
DI - APAP, avoid CYP inhibitors and inducers
Comments - Prophylactic anticonvulsants used with BMT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q 
Carboplatin
MOA
Indication
SE's
DI
Comments
A 
MOA - Platinum alkylating agent
Indication - HD, NHL
SE's - N/V, myelosuppression, neuropathy
DI - Mesna, immune suppressants
Comments - Dosed per GFR based on Calvert formula
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q 
Carfilzomib
MOA
Indication
SE's
DI
Comments
A 
MOA - Proteasome inhibitor
Indication - myeloma
SE's - heart failure, fatigue, nausea
DI - PGP/BCRP inhibitors
Comments - Dosed at maximum BSA 2.2m squared
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q 
Carmustine
MOA
Indication
SE's
DI
Comments
A

MOA - Alkylating agent
Indication - HD, NHL
SE’s - Myelosuppression, pulmonary fibrosis, n/v
DI - immunosuppressants, vaccines
Comments - dissolved in dehydrated alcohol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q 
Chlorambucil
MOA
Indication
SE's
DI
Comments
A 
MOA - Alkylating agent
Indication - CLL
SE's - myelosuppression, mucositis
DI - Other myelosuppressive agents
Comments - Take on empty stomach
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q 
Cisplatin
MOA
Indication
SE's
DI
Comments
A 
MOA - Platinum alkylating agent
Indication - NHL, HD
SE's - N/v, nephrotoxic, neuropathies
DI - Concomitant nephrotoxins
Comments - delayed nausea common
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q 
Cladribine
MOA 
Indication
SE's
DI
Comments
A 
MOA - purine analog
Indication - CLL, NHL, hairy cell leukemia
SE's - infections, myelosuppression
DI - live vaccines
Comments - Needs PJP prophylaxis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q 
Clofarabine
MOA
Indication
SE's
DI
Comments
A 
MOA - Purine analog
Indication - ALL< AML
SE's - Infections, myelosuppression, capillary leak syndrome
DI - Live vaccines
Comments - needs PJP prophylaxis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q 
Cyclophosphamide
MOA
Indication
SE's
DI
Comments
A

MOA - Alkylating agents
Indication - ALL, NHL, myeloma
SE’s - hemorrhagic cystitis, myelosuppression, SIADH
DI - CYP 2B6 inhibitors, CYP inducers
Comments - Mesna may be used as a bladder protectant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q 
Cytarabine
MOA
Indication
SE's
DI
Comments
A

MOA - Pyrimidine analogue
Indication - AML, NHL, HD
SE’s - Myelosuppression (high dose - conjunctivitis, cerebellar toxicity), acral erythema
DI - Concomitant immune suppressants
Comments - Steroid eye drops used with high dose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q 
Dacarbazine
MOA
Indication
SE's
DI
Comments
A

MOA - Alkylating agent
Indication - HD
SE’s - myeosuppression, n/v, photosensitivity
DI - CYP 1A2 oe 2E1 inhibitors or inducers
Comments - N/A

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q 
Daratumumab
MOA
Indication
SE's
DI
Comments
A

MOA - AntiCD 38 MAB
Indication - myeloma
SE’s - infusion reactions, myelosuppression
DI - none
Comments - interferes with RBC cross-matching

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q 
Dasatinib
MOA
Indication
SE's
DI
Comments
A 
MOA - Inhibits BCR-ABL kinase
Indication - CML, Ph+ALL
SE's - Fluid retention, rash, myelosuppression, pleural effusion
DI - CYP 3A4 inhibitors, acid reducers
Comments - Taken w/o regards to food
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q 
Daunorubicin
MOA
Indication
SE's
DI
Comments
A

MOA - DNA intercalator, free radical generation, topoisomerase II inhibitor
Indication- AML, ALL
SE’s - Vesicant, HF, arrhythmias, skin flare, urine discoloration, myelosuppression
DI - Avoid PGP and ABCB1 inducers or inhibitors
Comments - Lifetimes maximum of 500 mg/m squared suggested

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q 
Decitabine
MOA
Indication
SE's
DI
Comments
A 
MOA - Hypomethylating agent
Indication - AML, MDS
SE's - Myelosuppression, edema, nausea
DI - N/A
Comments - May take several cycles for full effect
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
``` Doxorubicin MOA Indication SE's DI Comments ```
MOA- DNA intercalator, free radical generation, topoisomerase II inhibitor Indication - NHL, HD, myeloma SE's - Vesicant, HF, arrhythmias, skin flare, urine discoloration, myelosuppression DI - Avoid CYO 3A4 and PGP inhibitors or inducers Comments - Lifetime maximum of 550 mg/m squared suggested
26
``` Dexamethasone MOA Indication SE's DI Comments ```
MOA - Lympholytic corticosteroid Indication - CLL, ALL, NHL, HD, myeloma SE's - Hyperglycemia, osteoporosis, mood changes, cataracts DI - Inhibits multiple CYP enzymes so be aware of other substrates with narrow therapeutic margins Comments - Take with food, infuse large doses slowly
27
``` Doxorubicin, Liposomal MOA Indication SE's DI Comments ```
MOA - DNA intercalator, free radical generation, topoisomerase II inhibitor Indication - myeloma SE's - hand foot syndrome, arrhythmia, HF, myelosuppression, infusion reactions DI - avoid CYP 3A4 inhibitors or inducers Comments - lifetime max of 550 mg/m2 suggested
28
``` Elotuzumab MOA Indication SE's DI Comments ```
``` MOA - Anti SLAMF-7 MAB Indication - Myeloma SE's - N/A DI - M/A Comments - Premedicate with H1 and H2 blocker and APAP ```
29
``` Etoposide MOA Indication SE's DI Comments ```
MOA - Topoisomerase II inhibitor Indication - NHL, AML, HD SE's - Myelosuppression, hypotension, nausea, stomatitis DI - Avoid CYP 3A4 inhibitors and inducers Comments - Infuse over 1 hour minimum
30
``` Fludarabine MOA Indication SE's DI Comments ```
``` MOA - Purine analog Indication - AML, CLL, NHL SE's - myelosuppression, encephalopathy, infections DI - Live vaccines Comments - Needs PJP prophylaxis ```
31
``` Gemtuzumab MOA Indication SE's DI Comments ```
MOA - Anti CD 33 MAB linked to an alkylating agent Indication - AML SE's - Myelosuppression, veni-occlusive disease DI - N/A Comments - Light sensitive compound
32
``` Hydroxyurea MOA Indication SE's DI Comments ```
``` MOA - Ribonucleotide reductase inhibitor Indication - AML, ALL, CML SE's - Myelosuppression, cutaneous ulcers, hyperuricemia DI - N/A Comments - Take without regards to food ```
33
``` Ibritumoman Y-90 MOA Indication SE's DI Comments ```
MOA- Anti CD 20MAB linked to I-131 Indication - NHI SE's - myelosuppression, infusion reactions DI - N/A Comments - Pre-dose targeting done to estimate location and extent of radiation and exposure, murine antibody
34
``` Ibrutinib MOA Indication SE's DI Comments ```
MOA - Bruton's tyrosine kinase inhibitor Indication - CLL, NHL SE's - hemorrhage, myelosuppression, infections, rash DI - Avoid CYP 3A4 inducers and strong 3A4 inhibitors Comments - Take on empty stomach
35
``` Idelalisib MOA Indication SE's DI Comments ```
MOA - PI-3 kinase inhibitor Indication - CLL SE's - Cutaneous reaction, increased glucose and triglycerides DI - Avoid CYP inducers, strong 3A4 inhibitors Comments - Take with food
36
``` Idarubicin MOA Indication SE's DI Comments ```
MOA - DNA intercalator, free radical generation, topoisomerase II inhibitor Indication- AML SE's - Myelosuppression, vesicant, colors urine red, radical arrhythmias and HF DI - Avoid PGP/ABCB1 inhibitors and inducers Comments - Maximum lifetimes dose of 150mg/m2
37
``` Ifosfamide MOA Indication SE's DI Comments ```
MOA - Alkylating agent Indication - NHL, HD SE's - Myelosuppression, encephalopathy, hemorrhagic cystitis, n/v DI - Avoid Cap 2A6, 2C19, and 3A4 inhibitors and inducers Comments - use with Mesna
38
``` Imatinib Mesylate (Gleevec) MOA Indication SE's DI Comments ```
``` MOA - BCR-ABL kinase inhibitor Indication - CML, Ph+ALL SE's - Edema , nausea, rash, myelosuppression DI - Inhibits CYP 3A4 Comments - Take with food ```
39
``` Interferon (Intron A) MOA Indication SE's DI Comments ```
MOA - Immune Modulator Indication - CML, NHL SE's - Flulike symptoms, depression, anorexia, myelosuppression DI - N/A Comments - May aggravate autoimmune disorders
40
``` Ixazomib (Ninlaro) MOA Indication SE's DI Comments ```
``` MOA - Proteasome inhibitor Indication - myeloma SE's - peripheral neuropathy, diarrhea, thrombocytopenia, edema DI - Avoid strong CYP 3A4 inducers Comments - Take on an empty stomach ```
41
``` L-asparaginase (Erwinaze) MOA Indication SE's DI Comments ```
MOA - Enzyme vs asparagine Indication - ALL SE's - Hypersensitivity reactions, pancreatitis, thrombosis, bleeding DI - Methotrexate, prednisone, vincristine Comments - Give after vincristine
42
``` Lenalidomide (Revlimid) MOA Indication SE's DI Comments ```
MOA - Immune modulating agent Indication - MDS, myeloma, NHL SE's - Thrombosis, myelosuppression, secondary leukemia DI - PGP inhibitors Comments - Teratogenic, take without regard to food
43
``` Lomustine (CeeNU) MOA Indication SE's DI Comments ```
``` MOA - Alkylating agent Indication- HD SE's - Melosuppression, CNS side effects, N/V DI - N/A Comments - Take on an empty stomach ```
44
``` Meclorethamine (mustargen) MOA Indication SE's DI Comments ```
``` MOA - Alkylating agent Indication - HD SE's - Myelosuppression, n/v DI - N/A Comments - N/A ```
45
``` Melphalan (Alkeran) MOA Indication SE's DI Comments ```
``` MOA - Alkylating agent Indication - Myeloma SE's - myelosuppression, rash, mucositis DI - N/A Comments - Use cryotherapy in mouth during high dose infusions, oral taken on empty stomach ```
46
``` Mercaptopurine (Purinethol) MOA Indication SE's DI Comments ```
``` MOA - Purine analog Indication - ALL SE's - Myelosuppression, diarrhea, mucositis DI - Allopurinol Comments - Take on an empty stomach ```
47
``` Methotrexate (Trexal) MOA Indication SE's DI Comments ```
MOA - Dihydrofolate reductase inhibitor Indication - NHL, ALL SE's - Myelosuppression, mucositis, nephrotoxic DI - PCN, NSAIDs, PPI, quinolones Comments - Need to alkalinize urine when administering high dose
48
``` Methylprednisone (Medrol) MOA Indication SE's DI Comments ```
MOA - Lympholytic corticosteroid Indication - CLL, ALL, NHL, HD, myeloma SE's - Hyperglycemia, osteoporosis, mood changes, cataracts DI - inhibits multiple CYP enzymes so be aware of other substrates with narrow therapeutic margins Comments - Take with food, infuse large doses slowly
49
``` Mitoxantrone (Novantrone) MOA Indication SE's DI Comments ```
MOA - DNA intercalator, free radical generation, topoisomerase II inhibitor Indication - AML, NHL SE's - Myelosuppression, vesicant, cardiotoxic (HF, arrythmias), colors urine blue-green DI - N/A Comments - Lifetime max dose 160 mg/m2
50
``` Nelabarine (Arranon) MOA Indication SE's DI Comments ```
``` MOA - Purine analog Indication - T-ALL and NHL SE's - Myelosuppression, neurotoxicity DI - Live vaccines Comments - Requires PJP prophylaxis ```
51
``` Nilotinib (Tasigna) MOA Indication SE's DI Comments ```
MOA - BCR-ABL kinase inhibitor Indication - CML, Ph+ALL SE's - Myelosuppression, QTc prolongation, pancreatitis DI - Avoid CYP 3A4 inhibitors and inducers. It is a moderate inhibitor of 2D6, 2C8/9 so avoid substrates with narrow margins Comments - Take on empty stomach
52
``` Nivolumab (Opdivo) MOA Indication SE's DI Comments ```
``` MOA - Anti PD-1 MAB Indication - HD SE's - Autoimmune conditions DI - N/A Comments - N/A ```
53
``` Obinatuzumab (Gazyva) MOA Indication SE's DI Comments ```
MOA - Anti CD 20 MAB Indication - CLL, NHL SE's - Infusion reactions, Hep B reactivation, PML, tumor lysis syndrome DI- N/A Comments - Concider holding anti-hypertensives the day of infusion
54
``` Ofatumumab (Arzerra) MOA Indication SE's DI Comments ```
MOA - Anti CD 20 MAB Indication - CLL SE's - Infusion reactions, Hep B reactivation, PML, tumor lysis syndrome DI - N/A Comments - Consider holding antihypertensives the day of infusion
55
``` Omacetaxine (Synribo) MOA Indication SE's DI Comments ```
MOA - protein synthesis inhibitor Indication - CML SE's - Myelosuppression, diarrhea, fatigue DI - N/A Comments - Delayed time to response but affects many mutated BCR-ABL forms
56
``` Oxaliplatin (Eloxatin) MOA Indication SE's DI Comments ```
``` MOA - Platinum alkylating agent Indication - NHL SE's - myelosuppression, n/v, neuropathy DI - N/A Comments - Do not touch or consume cold items for 72 hours postdose ```
57
``` Pabobinostat (Farydak) MOA Indication SE's DI Comments ```
``` MOA - Histone deacetylase inhibitor Indication - Myeloma SE's - diarrhea, fatigue, nausea DI - N/A Comments - N/A ```
58
``` Pegasparaginase (Oncaspar) MOA Indication SE's DI Comments ```
MOA - Enzyme vs asparagine Indication - ALL SE's - Hypersensitivity reactions, pancreatitis, thrombosis, bleeding DI - Methotrexate, prednisone Comments - Less antigenic than other asparaginase forms
59
``` Pentostatin (Nipent) MOA Indication SE's DI Comments ```
``` MOA - Purine analogue Indication - CLL, NHL SE's - myelosuppression, neurologic changes, infections DI - live vaccines Comments - need PJP prophylaxis ```
60
``` Pomalidomide (Pomalyst) MOA Indication SE's DI Comments ```
MOA - Immune modulating agent Indication - Myeloma SE's - Myelosuppression, thrombogenic, neuropathy, secondary AML DI - Avoid 1A2 and 3A4 inhibitors and inducers Comments - teratogenic
61
``` Ponatinib (Iclusig) MOA Indication SE's DI Comments ```
MOA - BCR-ABL kinase inhibitor Indication - CML SE's - hypertension, thrombosis, hepatic abnormalities, pancreatitis, HF DI - Avoid use with strong 3A4 inhibitors or inducers Comments - Take without regard to food
62
``` Pralatrexate (Folotyn) MOA Indication SE's DI Comments ```
MOA - Dihydrofolate reductase inhibitor Indication - NHL SE's - Myelosuppression, mucostis, nausea DI - Uricosurics, nephrotoxins, sulfa drugs Comments - Take B-12 and folate supplementation
63
``` Prednisone (Deltasone) MOA Indication SE's DI Comments ```
MOA - Lymptholytic corticosteroid Indication - CLL, ALL, NHL, HD, myeloma SE's -hyperglycemia, osteoporosis, mood changes, cataracts DI - Inhibits multiple CYP enzymes so be aware of other substrates with narrow therapeutic margins Comments - Take with food, infuse large doses slowly
64
``` Procarbazine (Matulane) MOA Indication SE's DI Comments ```
MOA - Alkylating agent Indication - NHL, HD SE's - myelosuppression, n/v, neurotoxicity DI - Amphetamines, meperidine, SSRI, tricyclics, ethanol Comments -Avoid fermented beverages and foods (MAOI)
65
``` Rituximab (Rituxan) MOA Indication SE's DI Comments ```
MOA - Anti CD 20 MAB Indication - NHL, CLL, ALL SE's - Infusion reactions, Hep B reactivation, PML, tumor lysis syndrome DI - N/A Comments - Consider holding antihypertensives the day of infusion
66
``` Romidepsin (Istodax) MOA Indication SE's DI Comments ```
``` MOA - Histone deacetylase inhibitor Indication - NHL SE's - fatigue, fever, n/v, myelosuppression DI - avoid CYP inhibitors and inducers Comments - N/A ```
67
``` Ruxolitinib (Jakafi) MOA Indication SE's DI Comments ```
MOA - Jak 1 and 2 kinase inhibitor Indication - myelofibrosis, polycythemia vera SE's - myelosuppression, peripheral edema, diarrhea, hepatic abnormalities DI - Avoid CYP inhibitors and inducers Comments - Rebound effect after stopping. Take without regard to food.
68
``` Temozolomide (Teomdar) MOA Indication SE's DI Comments ```
``` MOA - Alkylating agent Indication - NHL SE's - Myelosuppression, n/v, rash DI - N/A Comments - Administer consistently with regard to food, empty stomach preferred ```
69
``` Teniposide (Vumon) MOA Indication SE's DI Comments ```
``` MOA - Topoisomerase II inhibitor Indication - Pediatric leukemias SE's - myelosuppression, n/v, mucositis DI - phenytoin, carbamazepine, phenobarbital Comments - N/A ```
70
``` Thalidomide (Thalomid) MOA Indication SE's DI Comments ```
MOA - Immune modulating agent Indication - MDS, myeloma SE's - Sedation, neuropathy, constipation, thrombogenic DI - N/A Comments - Teratogenic, take on an empty stomach
71
``` Thioguanin (Tabloid) MOA Indication SE's DI Comments ```
``` MOA - purine analogue Indication - ALL SE's - myelosuppression, diarrhea, mucositis DI - N/A Comments - Take without regard to food ```
72
``` Thiotepa (Tepadina) MOA Indication SE's DI Comments ```
MOA - Alkylating agent Indication - NHL, HD SE's - myelosuppression, skin toxicity, mucositis DI - N/A Comments - Cower several times a day during high dose as secreted in sweat
73
``` Topotecan (Hycamtin) MOA Indication SE's DI Comments ```
``` MOA - Topoisomerase I inhibitor Indication - NHL, HD SE's - Myelosuppression, mucositis, n/v DI - phenytoin, cisplatin Comments - Give before cisplatin ```
74
``` Tositumomab I-131 (Bexxar) MOA Indication SE's DI Comments ```
MOA - Anti CD 20 MAB linked to Y-90 Indication - NHL SE's -myelosuppression, infusion reactions DI - N/A Comments - Pre-dose targeting done to estimate location and extent of radiation exposure, murine antibody thyroid protective agent given prior to dose
75
``` Tretinoin (Vesanoid) MOA Indication SE's DI Comments ```
MOA - Differentiating agent Indication - APL SE's - Hepatotoxic, headaches, skin changes DI - Avoid CYP 2C8 inhibitors and inducers Comments - Take with food
76
``` Venetoclax (Venclextra) MOA Indication SE's DI Comments ```
``` MOA - N/A Indication - CLL SE's - N/A DI - N/A Comments - N/A ```
77
``` Vinblastine (Velban) MOA Indication SE's DI Comments ```
``` MOA - Inhibits microtubule formation Indication - HD SE's - myelosuppression, neuropathy DI - Avoid CYP 3A4 inhibitors or inducers Comments - Fatal if given intrathecally ```
78
``` Vincristine (Oncovin) MOA Indication SE's DI Comments ```
``` MOA - Inhibits microtubule formation Indication - ALL, NHL, HD, myeloma SE's - Neuropathy, SIADH DI - Avoid CYP 3A4 inhibitors or inducers Comments - Fatal if given intrathecally ```
79
``` Vincristine, Liposomal (Marquibo) MOA Indication SE's DI Comments ```
MOA - Inhibits microtubule formation Indication - ALL SE's - Fever, constipation, myelsuppression, neuropathy DI - Avoid CYP 3A4, PGP, ABCB1 inhibitors and inducers Comments - Fatal if given intrathecally
80
``` Vorinostat (Zolinza) MOA Indication SE's DI Comments ```
``` MOA - Histone deacetylase inhibitor Indication - NHL SE's - diarrhea, edema, fatigue, hyperglycemia DI - Valproic acid Comments - Take with food ```

IDT Winter Term Cancer Chemotherapy Subclasses (2 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions